Alexion to Acquire LogicBio Therapeutics for ~$68M
Shots:
- Alexion to initiate a cash tender offer to acquire all of the issued & outstanding shares of LogicBio's common stock for $0.0001 par value/share at a purchase price of $2.07/share representing a 660% premium for $68M. The transaction is expected to be close in 4 to 6wks.
- The acquisition advances Alexion’s growth in genomic medicines through LogicBio’s technology, experienced rare disease R&D team, and expertise in pre-clinical development. LogicBio is developing gene-editing therapies to treat a pediatric rare disease
- GeneRid, developed by LogicBio is a novel method for precise gene insertion that makes use of a cell's inherent DNA repair mechanism to achieve long-lasting therapeutic protein expression levels
Ref: Businesswire | Image: Alexion
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
